18 May 2018 in Journal of Clinical Research in Pediatric Endocrinology
Adult epidemiological studies suggest that the rate of Restless Legs syndrome (RLS) in the general population may range from 5% to 15%. The aim of this study was to investigate the frequency of RLS in a community sample of obese adolescents aged 10-16 years and to assess the association with sleep quality and health-related glucose metabolism markers. The study group comprised 144 obese and overweight children aged 10-16 yearsand the control group consisted of 66 age-matched healthy children. The RLS Questionnaire devised by the International RLS Study and the Pittsburgh Sleep Quality Index (PSQI), where a score >5 indicates poor sleep quality, was used to assess sleep quality. Mean body mass index (BMI) of the overweight/obese and control groups were 30.5±0.5 and 18.7±0.2, respectively. The frequency of RLS was higher in the obese group (21.7%) than the overweight (3.4%) and control (1.5%) (p<0.001) groups. The frequency of a poor PSQI score was significantly higher (p<0.001) in the obese group (37.3%) than the control group (24.2%). The obese with RLS group also had poorer sleep quality scores than the non-RLS obese group. Many symptoms of sleep disruption were more common in obese patients with RLS and RLS was independently correlated with a high PSQI score [odds ratio (OR): 2.25, confidence interval (Cl): 0.96-5.28, p<0.001)] and an increased BMI z-score (OR: 8.87, Cl: 2.04-38.61, p<0.001). RLS is common in obese children and may be associated with altered sleep quality. Obese children with RLS need to be assessed since they may need support to improve their sleep quality.
26 February 2021 in Journal of Clinical Research in Pediatric Endocrinology
Bi-allelic mutations in the wolframin gene (WFS1) cause Wolfram syndrome 1 (WS1 or DIDMOAD) characterized by non-autoimmune diabetes mellitus, optic atrophy, diabetes insipidus, sensorineural deafness, urinary tract abnormalities, and neuropsychiatric disorders. Patients presenting with an incomplete phenotype of WS1 were evaluated using homozygosity mapping and subsequent whole-exome sequencing. Four unrelated consanguineous Turkish families, including seven affected children, and their unaffected parents and siblings were evaluated. Homozygosity mapping was performed, followed by whole-exome sequencing of WFS1. Mutations were classified according to results of “in silico” analyses, protein prediction, and functional consequences. Homozygosity mapping confirmed shared homozygous regions on chromosome 4 (chr4p16.1) between the affected individuals, that was absent in their unaffected siblings. Exome sequencing identified three novel (c.1215T>A, c.554G>A, c.1525_1540dup) and one known (c.1522_1523delTA) mutations in WFS1. All mutations were predicted to cause stop codon leading to early termination of protein synthesis and complete loss-of-function. All patients were found to be homozygous for the change, with parents and other unaffected siblings being carriers. Our study expands the mutation spectrum of WSF1 mutations with three novel mutations. Homozygosity mapping may provide enrichment for molecular genetic analysis and early diagnosis of WS1 patients with incomplete phenotype, particularly in consanguineous pedigrees.
1 September 2020 in Journal of Clinical Research in Pediatric Endocrinology
Objective: The aim was to determine the final adult height (FAH) achieved by recombinant human growth hormone (rhGH) treatment, the factors affecting (FAH) and the success of attaining the genetic potential. Methods: Data of 133 patients treated with rhGH therapy were reviewed retrospectively. Patients were grouped according to diagnosis, either isolated GH deficiency (IGHD) or multiple pituitary hormone deficiency (MPHD), and by sex, and pubertal status at the beginning of treatment. Results: The mean age of initiation of treatment was 12.3 +/- 2.18 years, and the mean duration of rhGH treatment was 3.65 +/- 1.5 years. The mean height standard deviation score (SDS) at diagnosis was -3.11 +/- 0.75 SD. All patients received a standardized GH dose of 0.033 mg/kg/day. Mean FAH-SDS was -1.8 +/- 0.77 and delta height-SDS (the change in height SDS between the beginning and end of treatment) was 1.28 +/- 0.94 SD. FAH-SDS was -1.79 +/- 0.86 SD in males; -1.82 +/- 0.64 in females (p =0.857); -1.94 +/- 0.71 at the beginning of treatment in pubertal patients and -1.68 +/- 0.81 in prepubertal patients (p = 0.056); -1.84 +/- 0.89 in patients with IGHD and -0.47 +/- 0.2 in patients with MPHD (p>0.05). In multiple regression analysis, First year delta height-SDS was the most predictive factor for both FAH-SDS and delta height-SDS. Conclusion: The majority of our patients achieved a final height compatible with their genetic potential as well as population standards when treated with rhGH even having started at a relatively late age. First year delta height-SDS was a predictive factor for FAH.
18 June 2025 in Indian Pediatrics
23 September 2024 in Journal of Clinical Ultrasound
24 June 2026 in Journal of Pediatric Endocrinology and Metabolism
Objectives: Children with multiple food allergies (MFA) often follow elimination diets that restrict major dietary sources of iodine, thereby increasing the risk of iodine deficiency. This study aimed to evaluate urinary iodine concentration (UIC) and thyroid function parameters in children with MFA and to compare these findings with those of age- and sex-matched healthy controls. Methods: In this prospective cross-sectional study, 47 children aged 0–13 years with IgE-mediated MFA on elimination diets were compared with 52 age- and sex-matched healthy controls between October 2022 and March 2024. Serum thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), and free thyroxine (fT4) were measured using electrochemiluminescence immunoassay, and UIC was determined by inductively coupled plasma mass spectrometry (ICP-MS). Anthropometric parameters were also assessed. Results: Serum TSH, fT3, and fT4 levels did not differ significantly between the MFA and control groups (p>0.05). However, median UIC was significantly lower in the MFA group [86 μg/L (IQR: 50–115)] compared with controls [126 μg/L (IQR: 105–134)] (p=0.001), indicating mild iodine deficiency in the MFA group. No cases of overt hypothyroidism were detected. Conclusions: Children with multiple food allergies receiving elimination diets are at increased risk of mild iodine deficiency, even in iodine-sufficient regions, although overt thyroid dysfunction may not yet be evident. These findings highlight the importance of routine monitoring of iodine status and early nutritional interventions in this vulnerable population.